Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.68 |
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.68 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.68 |
| ▸ | GLS | O94925 | 3/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21443390 | 0.93 | NPC1 (0.66) | NPC1RAB9AKMT2AMEN1SRC | |
| SCHEMBL31654008 | 0.82 | NPC1 (1.00) | NPC1RAB9AKMT2AMEN1SRC | |
| SCHEMBL21360253 | 0.82 | NPSR1 (0.49) | NPC1RAB9AKMT2AMEN1SRC | |
| SCHEMBL31060226 | 0.81 | NPC1 (1.00) | NPC1RAB9AKMT2AMEN1SRC | |
| SCHEMBL14986988 | 0.80 | GLS (1.00) | NPC1RAB9AKMT2AMEN1SRC | |
| SCHEMBL14986984 | 0.80 | GLS (0.73) | GLS | |
| SCHEMBL15655625 | 0.77 | NPC1 (0.82) | NPC1RAB9AKMT2AMEN1SRC | |
| SCHEMBL11480689 | 0.75 | CSNK2A2 (0.83) | NPC1RAB9AKMT2AMEN1SRC | |
| SCHEMBL2664519 | 0.75 | SMN1; SMN2 (0.67) | NPC1RAB9AKMT2AMEN1SRC | |
| SCHEMBL10991652 | 0.75 | GLS (0.72) | NPC1RAB9AKMT2AMEN1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922832-B1 | GLUTAMINASE INHIBITORS AND METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10414740-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| WO-2014081925-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011574-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | NPC1 3268/4885RAB9A 2293/4885KMT2A 1144/4885 |
| US-10414740-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | NPC1 3268/4885RAB9A 2293/4885KMT2A 1144/4885 |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | NPC1 3177/4885RAB9A 2289/4885KMT2A 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.